- Conditions
- Platinum Sensitive Ovarian Cancer, Ovarian Cancer
- Interventions
- FRα peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF) Alone
- Biological · Drug
- Lead sponsor
- Marker Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,351
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- GM2-KLH vaccine, QS21
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Influenza
- Interventions
- 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
- Biological
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 5 Years to 8 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Astrocytoma, Oligo-Astrocytoma, Glioma
- Interventions
- GAA/TT-peptide vaccine and poly-ICLC
- Biological
- Lead sponsor
- Ian F. Pollack, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
- Conditions
- Renal Cancer
- Interventions
- Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
- Biological · Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC, Radical Prostatectomy
- Biological · Procedure
- Lead sponsor
- Ashutosh Kumar Tewari
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer's Disease
- Interventions
- LY2062430, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 13 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Newton, Kansas • Syracuse, New York • Ellensburg, Washington
- Conditions
- Kidney Transplant Recipients, Liver Transplant Recipients
- Interventions
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
- Conditions
- Influenza Immunisation, Healthy Volunteers
- Interventions
- Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 2 and adjuvant, Quadrivalent RIV with 2018-2019 NH H3 strain, Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more
- Conditions
- Plasma Cell Neoplasm
- Interventions
- Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Smallpox
- Interventions
- Vaccinia virus: ACAM2000 smallpox vaccine, vaccinia virus (calf lymph): Dryvax
- Biological
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 353 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Lenexa, Kansas • Springfield, Missouri + 1 more
- Conditions
- Immunization, Vaccination
- Interventions
- STOP-HPV communication intervention
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Itasca, Illinois
- Conditions
- Diarrhea
- Interventions
- Heat-Labile Enterotoxin of E. coli (LT), Placebo
- Biological
- Lead sponsor
- Intercell USA, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Anaheim, California • South Miami, Florida • Lenexa, Kansas + 2 more
- Conditions
- B Cell Lymphoma, Follicular Lymphoma, Neoplasm
- Interventions
- Id-KLH Vaccine, QS-21 (Stimulation-QS-21) Drug
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Meningococcal Meningitis, Meningococcal Infections
- Interventions
- NmVac4-A/C/Y/W-135-DT™
- Biological
- Lead sponsor
- JN-International Medical Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Towson, Maryland
- Conditions
- HIV Infections
- Interventions
- HIV gp120/NefTat/AS02A Vaccine
- Biological
- Lead sponsor
- Marcus Altfeld, M.D., Ph.D.
- Individual
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Diabetes type1, Autoimmune Diabetes
- Interventions
- Bacillus Calmette-Guérin, Saline Injection
- Biological
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Pneumonia
- Interventions
- PCV7, Prevnar®, Pneumovax 23
- Biological
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 70 Years to 79 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- HPV
- Interventions
- brief informational intervention to promote HPV vaccine acceptance
- Behavioral
- Lead sponsor
- Syracuse University
- Other
- Eligibility
- 11 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- COVID-19, Sleep, Immunization; Infection, Physical Inactivity, Blood Pressure, Diet Habit, Mental Health Wellness 1
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana
- Conditions
- Behavior, Health, Flu, Flu Vaccination
- Interventions
- Pre-visit patient text messaging, Default pended order, Monthly peer comparison feedback, High risk bidirectional pre-visit text messaging
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26,248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Paclitaxel, Trastuzumab, Pertuzumab, Docetaxel, Carboplatin, Ultrasound Imaging, Biopsy Procedure, Biospecimen Collection
- Biological · Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cytomegaloviral Infection, Hematopoietic and Lymphoid System Neoplasm
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine
- Procedure · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Buffalo, New York